ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2022
State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer's disease.Scientific reports · 2026Article
- Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system.The journal of prevention of Alzheimer's disease · 2026Article
- Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.Neurodegenerative disease management · 2026Review
- Non-invasive screening of alzheimer's disease via label-free tri-spectral retinal imaging.Scientific reports · 2026Article
- Machine learning-derived biomarker cutoffs for Alzheimer's disease: Validation and application in preclinical and prodromal phases.iScience · 2025Article
- Article
- Psychological impact of biomarker-assisted diagnosis of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.Journal of personalized medicine · 2025Article
- Fully Automated Measurement of GFAP in CSF Using the LUMIPULSEInternational journal of molecular sciences · 2025Article
- Role ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Using machine learning and electronic health record (EHR) data for the early prediction of Alzheimer's Disease and Related Dementias.The journal of prevention of Alzheimer's disease · 2025Article
- Optical signature of retinal Tau fibrillation.Scientific reports · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.Diagnostics (Basel, Switzerland) · 2025Article
- Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort.Brain communications · 2025Article
- ADNI Biomarker Core: A review of progress since 2004 and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Rethinking the diagnosis of primary progressive aphasia: current challenges and future directions.Frontiers in aging neuroscience · 2025Article
- Enhancing clinical awareness: retrospective analysis of neurosyphilis cases and diagnostic predictors for early recognition and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 15 institutions in 7 countries.
Funding
Abstract
Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. Appropriate incorporation of cerebrospinal fluid biomarker analysis in clinical practice is an essential step toward system readiness for accommodating the demand of AD diagnosis and proper use of DMTs-once they become available. However, the use of lumbar puncture (LP) in individuals with suspected neurodegenerative diseases such as AD is inconsistent, and the perception of its utility and safety differs considerably among medical specialties as well as among regions and countries. This review describes the state-of-the-art evidence concerning the safety profile of LP in older adults, discusses the risk factors for LP-associated adverse events, and provides recommendations and an outlook for optimized use and global implementation of LP in individuals with suspected AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.